Stapled peptide-based membrane fusion inhibitors of hepatitis C virus

被引：61

作者：

Cui, Hong-Kui ^{[1
]}

Qing, Jie ^{[1
]}

Guo, Ye ^{[1
]}

Wang, Yu-Jia ^{[1
]}

Cui, Li-Jia ^{[2
,3
]}

He, Tian-Hua ^{[2
,3
]}

Zhang, Linqi ^{[2
,3
]}

Liu, Lei ^{[1
]}

机构：

[1] Tsinghua Univ, Dept Chem, Tsinghua Peking Ctr Life Sci,Minist Educ, Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China

[2] Tsinghua Univ, Sch Med, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China

[3] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Beijing 100084, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2013年 / 21卷 / 12期

基金：

中国国家自然科学基金;

关键词：

Hepatitis C virus; Stapled peptide; Protein-protein interaction; CELL-CULTURE SYSTEMS; B TYPE-I; OLEFIN METATHESIS; ALPHA-HELICES; BH3; HELIX; CD81; ENTRY; INFECTION; PROTEINS; RECEPTOR;

D O I：

10.1016/j.bmc.2013.02.011

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The strategy of peptide stapling was used to develop new molecules to inhibit the hepatitis C virus infection via disrupting the binding of HCV envelope glycoprotein E2 with human cell surface protein CD81. The peptide sequence was designed based on the large extra-cellular loop of CD81 with known importance in the HCV E2 binding interaction. Our results showed that the stapled peptides exhibited significantly higher alpha-helicity and proteolytic stability as compared to their linear peptide counterpart. The optimal compound was found to have an EC50 value of ca. 17-39 mu M against different HCV subtypes and represented a new HCV membrane fusion inhibitor. (C) 2013 Elsevier Ltd. All rights reserved.

引用

下载

页码：3547 / 3554

页数：8

共 50 条

[11] Peptide inhibitors of hepatitis C virus core oligomerization and virus production
Kota, S.
Coito, C.
Mousseau, G.
Lavergne, J. -P.
Strosberg, A. D.
JOURNAL OF GENERAL VIROLOGY, 2009, 90 : 1319 - 1328
[12] Stapled Peptides-A Useful Improvement for Peptide-Based Drugs
Moiola, Mattia
Memeo, Misal G.
Quadrelli, Paolo
MOLECULES, 2019, 24 (20):
[13] Peptide-based entry inhibitors for influenza
Voss, Thomas
LeBlanc, Christopher
Barbercheck, Joseph
Kaplan, Bryan
Wilson, Russell
Robert, Garry
ANTIVIRAL RESEARCH, 2008, 78 (02) : A18 - A18
[14] Peptide-based entry inhibitors for paramyxoviruses
LeBlanc, Christopher
Wilson, Russell
Kulkosky, Peter
Garry, Robert
Voss, Thomas
ANTIVIRAL RESEARCH, 2008, 78 (02) : A43 - A43
[15] Peptide-based inhibitors of amyloid assembly
Sciarretta, Kimberly L.
Gordon, David J.
Meredith, Stephen C.
AMYLOID, PRIONS, AND OTHER PROTEIN AGGREGATES, PT C, 2006, 413 : 273 - 312
[16] Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): Model compounds towards small molecule inhibitors
Oscarsson, K
Poliakov, A
Oscarson, S
Danielson, UH
Hallberg, A
Samuelsson, B
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (13) : 2955 - 2963
[17] Peptide-based inhibitors of the phagocyte NADPH oxidase
El-Benna, Jamel
Dang, Pham My-Chan
Perianin, Axel
BIOCHEMICAL PHARMACOLOGY, 2010, 80 (06) : 778 - 785
[18] Identificaton and analysis of peptide-based inhibitors of the HCVIRES
Orwig, KS
Dix, TA
BIOPOLYMERS, 2003, 71 (03) : 392 - 392
[19] Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases
Pluda, Stefano
Mazzocato, Ylenia
Angelini, Alessandro
FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
[20] Conjugation of spermine enhances cellular uptake of the stapled peptide-based inhibitors of p53-Mdm2 interaction
Muppidi, Avinash
Li, Xiaolong
Chen, Jiandong
Lin, Qing
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (24) : 7412 - 7415

← 1 2 3 4 5 →